Previous close | 3.8898 |
Open | 3.9100 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 3.9100 - 4.2800 |
52-week range | 1.9200 - 8.0800 |
Volume | |
Avg. volume | 4,724 |
Market cap | 787,071 |
Beta (5Y monthly) | 1.06 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.2670 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million upfront payment, and is eligible to receive up to $ 231 million in clinical, regulatory and commercial milestone payments in addition to tiered royalties from mid double digits to low twenties based on net sales of lanifibranor in Japan and South Korea.Pending regulatory approvals, Hepalys Pharma, Inc.
Daix (France), Long Island City (New York, United States), August 31, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today announced an approximately €35.7 million financing. The financing consists of two transactions: (i) a capital increase rese
Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million2, and long-term deposit at €9.3 million3 as of June 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectivelyRevenues of €1.9 m in H1 2023, compared to €0.1 million for the same period in 2022 Daix (France), Long Island City (New York, United States), July 27, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company f